Cyclobenzaprine

CHEMBL669 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
275.4 g/mol
LogP
5.2
Phase
4

A centrally acting muscle relaxant structurally related to tricyclic antidepressants that relieves muscle spasm and associated pain by acting on the brain stem. It is used short-term for acute musculoskeletal conditions and should not be used for more than two to three weeks.

Molekularmasse

275,4000 g/mol

LogP

5,20

TPSA

3,20 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Wirkmechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCC=C1c2ccccc2C=Cc2ccccc21

InChI

InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3

Molecular Formula

C20H21N

HBD / HBA

- / 1

Rotierbare Bindungen

3

Schwere Atome

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A centrally acting muscle relaxant structurally related to tricyclic antidepressants that relieves muscle spasm and associated pain by acting on the brain stem. It is used short-term for acute musculoskeletal conditions and should not be used for more than two to three weeks.

Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.

Yes, Cyclobenzaprine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL669. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2895. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.